Compare AZZ & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | IDYA |
|---|---|---|
| Founded | 1956 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.6B |
| IPO Year | 1994 | 2019 |
| Metric | AZZ | IDYA |
|---|---|---|
| Price | $153.24 | $36.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $141.80 | $52.86 |
| AVG Volume (30 Days) | 216.2K | ★ 663.4K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | ★ 486.59 | 61.90 |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $1,061,817,000.00 | $218,710,000.00 |
| Revenue This Year | $7.03 | N/A |
| Revenue Next Year | $4.25 | $201.05 |
| P/E Ratio | $87.99 | ★ N/A |
| Revenue Growth | 14.53 | ★ 3024.43 |
| 52 Week Low | $92.98 | $23.23 |
| 52 Week High | $162.20 | $40.58 |
| Indicator | AZZ | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 53.90 |
| Support Level | $132.06 | $34.29 |
| Resistance Level | $152.83 | $37.82 |
| Average True Range (ATR) | 3.87 | 1.13 |
| MACD | 0.19 | -0.06 |
| Stochastic Oscillator | 67.64 | 66.45 |
AZZ Inc is a provider of galvanizing and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of AZZ Metal Coatings, AZZ Precoat Metals, and AZZ Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company operates in the United States and Canada.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.